Producto añadido correctamente al carrito.

discount label
H-CLAVEEVSLRK-OH
Ver en 3D

Biosynth logo

H-CLAVEEVSLRK-OH

Ref. 3D-PP47138

1mg
248,00 €
10mg
292,00 €
100mg
481,00 €
Entrega estimada en Estados Unidos, el Jueves 9 de Enero de 2025

Información del producto

Nombre:
H-CLAVEEVSLRK-OH
Descripción:

Peptide H-CLAVEEVSLRK-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-CLAVEEVSLRK-OH include the following: Association of nucleophosmin negatively regulates CXCR4-mediated G protein activation and chemotaxis W Zhang , JM Navenot, NM Frilot, N Fujii - Molecular pharmacology, 2007 - ASPEThttps://molpharm.aspetjournals.org/content/72/5/1310.short Monitoraggio delle risposte T-cellulari specifiche contro la proteina NPM1 mutata in pazienti con leucemia acuta mieloide con mutazione di NPM1: correlazione con l' S TEDDE - 2017 - morethesis.unimore.ithttps://morethesis.unimore.it/theses/available/etd-09192017-142541/ Genetic alterations and checkpoint expression: mechanisms and models for drug discovery S Ding, S Li, S Zhang, Y Li - Regulation of Cancer Immune Checkpoints , 2020 - Springerhttps://link.springer.com/chapter/10.1007/978-981-15-3266-5_10 HLA class I genotype Is associated with relapse risk after allogeneic stem cell transplantation for NPM1-mutated acute myeloid leukemia R Narayan, A Niroula , T Wang, M Kuxhausen - and cellular therapy, 2023 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2666636723012046 A"grappling hook" interaction balances self-assembly and chaperone activity of Nucleophosmin 1 M Saluri , A Leppert , GV Gese , C Sahin , D Lama - bioRxiv, 2022 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2022.09.29.510028.abstract A"grappling hook" interaction connects self-assembly and chaperone activity of Nucleophosmin 1 M Saluri , A Leppert , GV Gese , C Sahin , D Lama - PNAS , 2023 - academic.oup.comhttps://academic.oup.com/pnasnexus/article-abstract/2/2/pgac303/6973215 The interplay between the genetic and immune landscapes of AML: mechanisms and implications for risk stratification and therapy LM Mendez , RR Posey, PP Pandolfi - Frontiers in Oncology, 2019 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fonc.2019.01162/full Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia G Koutsoumpli, DI van der Lee, NC Groenland - Blood, 2022 - ashpublications.orghttps://ashpublications.org/blood/article/140/Supplement%201/10243/489588 Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia F Forghieri, G Riva, I Lagreca, P Barozzi - International Journal of , 2021 - mdpi.comhttps://www.mdpi.com/1422-0067/22/17/9159 Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia F Forghieri, G Riva, I Lagreca, P Barozzi, D Vallerini - Oncotarget, 2019 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368236/ Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia DI van der Lee, RM Reijmers - The Journal of , 2019 - Am Soc Clin Investighttps://www.jci.org/articles/view/97482 Mutated NPM1 as target for immunotherapy of acute myeloid leukemia DI Van Der Lee, HM Bijen, RS Hagedoorn - Blood, 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119806857 An HLA-A* 11: 01-binding neoantigen from mutated NPM1 as target for TCR gene therapy in AML DI van der Lee, G Koutsoumpli, RM Reijmers - Cancers, 2021 - mdpi.comhttps://www.mdpi.com/2072-6694/13/21/5390 Could Targeting NPM1c+ Misfolding Be a Promising Strategy for Combating Acute Myeloid Leukemia? D Florio, D Marasco - International Journal of Molecular Sciences, 2024 - mdpi.comhttps://www.mdpi.com/1422-0067/25/2/811 Leucemia Acuta Mieloide con mutazione del gene della nucleofosmina (NPM1): dalle caratteristiche immunoistochimiche alle risposte immunologiche A PAOLINI - 2019 - morethesis.unimore.ithttps://morethesis.unimore.it/theses/available/etd-12142018-102509/ Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules A Liso , D Colau, R Benmaamar, A De Groot , W Martin - Leukemia, 2008 - nature.comhttps://www.nature.com/articles/2404887

Aviso:
Nuestros productos están destinados únicamente para uso en laboratorio. Para cualquier otro uso, por favor contáctenos.
Marca:
Biosynth
Almacenamiento de larga duración:
Notas:

Propiedades químicas

MDL:
Punto de fusión:
Punto de ebullición:
Punto de inflamabilidad:
Densidad:
Concentración:
EINECS:
Merck:
Código HS:

Información de peligrosidad

Número UN:
Cantidad exceptuada (EQ):
Clase:
Frases H:
Frases P:
Prohibido volar:
Información de peligrosidad:
Grupo de empaquetado:
Cantidad limitada (LQ):

Consulta técnica sobre: 3D-PP47138 H-CLAVEEVSLRK-OH

Use el carrito para solicitar presupuestos o pedidos

Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.

* Campos obligatorios
¡Bienvenido a CymitQuimica!Utilizamos cookies para mejorar su visita. No incluimos publicidad.

Consulte nuestra Política de Cookies para obtener más información o ajuste sus preferencias en "Configurar".